Category: Jurisdictions
-
Novo Nordisk signs GLP-1 licensing agreement with China’s Hengrui Pharma
Novo Nordisk and Hengrui Pharma’s agreement, subject to antitrust approval, will allow Novo to obtain exclusive rights to develop, manufacture, and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macao, and Taiwan.
-
Via annual Bridge Summit to focus on AI licensing
Via Licensing Alliance’s fourth-ever annual Bridge Summit, due to take place next week, will feature AI infrastructure and data center licensing discussions throughout its conference, as well as licensor meetings dedicated to its newly launched DRAM pool.
-
Jury awards Burford-funded Taction $5.7B against Apple, but verdict appears not too likely to be affirmed; even JMOL appears possible
It will not be easy to defend this record patent damages verdict, given not only its outsized amount but also the deficiencies of the record that Apple has already alleged.
-
French consumer rights group urges Disney+ to compensate customers for switching off 4K following InterDigital injunctions
While Disney+ switched 4K back on again using a workaround in Germany, the streaming giant has not done the same in its other markets, including France.
-
Mylan seeks declaratory judgment against Novo Nordisk over newly issued Wegovy patent, aiming to preempt a new Delaware lawsuit
Mylan has asked a Delaware court to declare a newly issued Novo Nordisk Wegovy patent invalid and not infringed, opening a new front in their long-running Hatch-Waxman fight over generic semaglutide.
-
EPO board of appeal rejects claim-saving approach to ambiguous amendments
The EPO Board of Appeal has rejected a claim-saving approach to ambiguous amendments in a Philip Morris e-cigarette patent dispute, holding that unresolved ambiguity can broaden a claim and create added-matter problems.
-
Federal court dismisses Entresto antitrust suit against Novartis: patent listing in Orange Book was proper
Judge Liman held that the U.S. Patent No. 8,101,659 claims the active ingredients on Entresto’s FDA label, so its Orange Book listing was proper, ending a payor’s antitrust case with prejudice.
-
UPC Brussels limits interveners’ ability to pursue independent claims
The UPC’s Brussels LD has rejected the NIH’s bid to be treated as a co-claimant in 2seventy Bio’s infringement case, holding that interveners are limited to supporting the claims of the party they join and cannot pursue an independent litigation position.
-
Hong Kong’s pledge to become IP trading center is ‘game-changer’, but requires more than policy and financing platforms
Lawyers from both HK and China shared their thoughts on Hong Kong’s new Five-Year Plan, which pledges to transform it into a regional IP trading center. While they were generally positive, some were skeptical, highlighting that China’s own experience suggests government policy and trading platforms alone cannot create a liquid market for IP.